Atezolizumab is effective and well-tolerated in patients with extensive-stage small-cell lung cancer (ES-SCLC). We examined atezolizumab's efficacy and safety in 42 Japanese patients with ES-SCLC via a subanalysis of the phase I/III IMpower133 trial. Addition of atezolizumab to chemotherapy improved overall survival and was generally well-tolerated, thus offering a potentially new treatment for Japanese patients with ES-SCLC.
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
- Cancer Research